👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Roche stock: BofA upgrades to Buy, Deutsche Bank cuts to Sell

Published 2024-09-13, 05:24 a/m
© Reuters.
RO
-

Investing.com -- Swiss drugs and diagnostic maker, Roche (SIX:RO) is seeing mixed opinions from two big brokerages. BofA securities has upgraded Roche to a "buy," setting a target price of CHF 340, due to a positive outlook on the company's growth. 

Meanwhile, Deutsche Bank (ETR:DBKGn) has downgraded the stock to "sell," with a target price of CHF 235, citing worries about Roche's R&D productivity and competitive standing.

BofA's upgrade to "buy" reflects a positive outlook on Roche's future. The brokerage believes that Roche's earnings per share (EPS) downgrade cycle, which saw a significant drop over the past three years, has now reached its nadir. 

BofA projects a recovery in Roche’s EPS, forecasting an FY25 estimate that exceeds consensus by 3%. This expected rebound is due to a stronger-than-expected performance in key products like Xolair, used for asthma and hives, Vabysmo, targeting retinal diseases, and improving pharmaceutical margins.

Central to BofA's optimism is Roche’s pipeline, which includes three critical assets with the potential to each generate more than $5 billion in peak sales. 

These assets include Giredestrant, an oral selective estrogen receptor degrader (SERD) for breast cancer, which BofA projects will achieve peak sales of CHF 7 billion (risk-adjusted to CHF 2.8 billion). 

Fenebrutinib, a BTK inhibitor for multiple sclerosis, is expected to reach peak sales of CHF 5 billion (risk-adjusted to CHF 1.8 billion), while Prasinezumab, a potential first-in-class therapy for Parkinson’s disease, could see peak sales of CHF 5 billion (risk-adjusted to CHF 750 million). 

Reflecting confidence in Roche’s ability to return to growth, BofA has set a price target of CHF 340, applying a 16x FY25E P/E ratio.

BofA is particularly enthusiastic about Giredestrant, despite concerns about past failures of similar drugs. 

The brokerage expects positive outcomes from ongoing Phase III trials, differentiating Giredestrant from previous disappointments in this category.

On the other hand, Deutsche Bank's downgrade to 'sell' flags concerns about Roche’s direction and R&D productivity. The brokerage is wary of Roche’s diminishing innovation, especially in oncology, which has been a core area for the company

Deutsche Bank is skeptical about Roche's ability to maintain its competitive edge, potentially leading to weaker long-term growth.

Additionally, Deutsche Bank has raised red flags regarding Roche's late and undifferentiated entry into the obesity market. 

Despite previous excitement about Roche’s obesity assets, recent data suggests these products may not offer differentiation from competitors. 

This has led Deutsche Bank to reduce its target price from to CHF 235 CHF 265, applying a 13x FY24 P/E ratio.

The brokerage’s downgrade also reflects disappointment in Roche's obesity pipeline, which, despite initial promise, appears to lack the disruptive potential needed to compete effectively in this high-growth sector. 

Deutsche Bank also voices concerns about Roche's oncology pipeline, particularly in immuno-oncology, an area that has previously driven significant growth.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.